Literature DB >> 20959471

Danger signaling protein HMGB1 induces a distinct form of cell death accompanied by formation of giant mitochondria.

Georg Gdynia1, Martina Keith, Jürgen Kopitz, Marion Bergmann, Anne Fassl, Alexander N R Weber, Julie George, Tim Kees, Hans-Walter Zentgraf, Otmar D Wiestler, Peter Schirmacher, Wilfried Roth.   

Abstract

Cells dying by necrosis release the high-mobility group box 1 (HMGB1) protein, which has immunostimulatory effects. However, little is known about the direct actions of extracellular HMGB1 protein on cancer cells. Here, we show that recombinant human HMGB1 (rhHMGB1) exerts strong cytotoxic effects on malignant tumor cells. The rhHMGB1-induced cytotoxicity depends on the presence of mitochondria and leads to fast depletion of mitochondrial DNA, severe damage of the mitochondrial proteome by toxic malondialdehyde adducts, and formation of giant mitochondria. The formation of giant mitochondria is independent of direct nuclear signaling events, because giant mitochondria are also observed in cytoplasts lacking nuclei. Further, the reactive oxygen species scavenger N-acetylcysteine as well as c-Jun NH(2)-terminal kinase blockade inhibited the cytotoxic effect of rhHMGB1. Importantly, glioblastoma cells, but not normal astrocytes, were highly susceptible to rhHMGB1-induced cell death. Systemic treatment with rhHMGB1 results in significant growth inhibition of xenografted tumors in vivo. In summary, rhHMGB1 induces a distinct form of cell death in cancer cells, which differs from the known forms of apoptosis, autophagy, and senescence, possibly representing an important novel mechanism of specialized necrosis. Further, our findings suggest that rhHMGB1 may offer therapeutic applications in treatment of patients with malignant brain tumors. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20959471     DOI: 10.1158/0008-5472.CAN-10-0204

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  31 in total

Review 1.  Please stand by: how oncolytic viruses impact bystander cells.

Authors:  Leslee Sprague; Lynne Braidwood; Joe Conner; Kevin A Cassady; Fabian Benencia; Timothy P Cripe
Journal:  Future Virol       Date:  2018-08-08       Impact factor: 1.831

2.  Peripheral Blood Mononuclear Cells Demonstrate Mitochondrial Damage Clearance During Sepsis.

Authors:  Bryan D Kraft; Lingye Chen; Hagir B Suliman; Claude A Piantadosi; Karen E Welty-Wolf
Journal:  Crit Care Med       Date:  2019-05       Impact factor: 7.598

3.  Knockdown of HMGB1 in tumor cells attenuates their ability to induce regulatory T cells and uncovers naturally acquired CD8 T cell-dependent antitumor immunity.

Authors:  Zuqiang Liu; Louis D Falo; Zhaoyang You
Journal:  J Immunol       Date:  2011-06-03       Impact factor: 5.422

4.  Intramyocellular lipid droplets increase with progression of cachexia in cancer patients.

Authors:  Nathan A Stephens; Richard J E Skipworth; Alisdair J Macdonald; Carolyn A Greig; James A Ross; Kenneth C H Fearon
Journal:  J Cachexia Sarcopenia Muscle       Date:  2011-05-31       Impact factor: 12.910

Review 5.  p53: exercise capacity and metabolism.

Authors:  Ping-Yuan Wang; Jie Zhuang; Paul M Hwang
Journal:  Curr Opin Oncol       Date:  2012-01       Impact factor: 3.645

Review 6.  Potential role of High mobility group box 1 in hepatocellular carcinoma.

Authors:  Rong-Rong Zhou; Xu-Yuan Kuang; Yan Huang; Ning Li; Ming-Xiang Zou; Dao-Lin Tang; Xue-Gong Fan
Journal:  Cell Adh Migr       Date:  2014       Impact factor: 3.405

7.  High mobility group box 1 (HMGB1) phenotypic role revealed with stress.

Authors:  Daolin Tang; Rui Kang; Bennett Van Houten; Herbert J Zeh; Timothy R Billiar; Michael T Lotze
Journal:  Mol Med       Date:  2014-08-19       Impact factor: 6.354

8.  Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer.

Authors:  Assia L Angelova; Svitlana P Grekova; Anette Heller; Olga Kuhlmann; Esther Soyka; Thomas Giese; Marc Aprahamian; Gaétan Bour; Sven Rüffer; Celina Cziepluch; Laurent Daeffler; Jean Rommelaere; Jens Werner; Zahari Raykov; Nathalia A Giese
Journal:  J Virol       Date:  2014-02-26       Impact factor: 5.103

9.  miR-218 opposes a critical RTK-HIF pathway in mesenchymal glioblastoma.

Authors:  Lijoy K Mathew; Nicolas Skuli; Vera Mucaj; Samuel S Lee; Pascal O Zinn; Pratheesh Sathyan; Hongxia Z Imtiyaz; Zhongfa Zhang; Ramana V Davuluri; Shilpa Rao; Sriram Venneti; Priti Lal; Justin D Lathia; Jeremy N Rich; Brian Keith; Andy J Minn; M Celeste Simon
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-24       Impact factor: 11.205

10.  Life after death: targeting high mobility group box 1 in emergent cancer therapies.

Authors:  Z Sheng Guo; Zuqiang Liu; David L Bartlett; Daolin Tang; Michael T Lotze
Journal:  Am J Cancer Res       Date:  2013-01-18       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.